Viking Therapeutics (VKTX) Short Interest Ratio & Short Volume $31.11 -0.18 (-0.58%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$31.05 -0.06 (-0.19%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Viking Therapeutics Short Interest DataViking Therapeutics (VKTX) has a short interest of 32,100 shares, representing 0.03% of the float (the number of shares available for trading by the public). This marks a -99.89% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 4.05 million shares to cover all short positions.Current Short Interest32,100 sharesPrevious Short Interest28,470,000 sharesChange Vs. Previous Month-99.89%Dollar Volume Sold Short$850.65 thousandShort Interest Ratio0.2 Days to CoverLast Record DateJune 30, 2025Outstanding Shares112,310,000 sharesShort Percent of Float0.03%Today's Trading Volume2,829,639 sharesAverage Trading Volume4,050,134 sharesToday's Volume Vs. Average70% Short Selling Viking Therapeutics? Sign up to receive the latest short interest report for Viking Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVKTX Short Interest Over TimeVKTX Days to Cover Over TimeVKTX Percentage of Float Shorted Over Time Viking Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/202532,100 shares $850.65 thousand -99.9%0.0%0.2 $26.50 6/15/202528,470,000 shares $742.50 million +6.6%26.4%7.5 $26.08 5/31/202526,710,000 shares $720.64 million +4.6%25.2%6.9 $26.98 5/15/202525,540,000 shares $699.80 million -3.8%24.0%6.2 $27.40 4/30/202526,540,000 shares $766.21 million +4.2%N/A5.7 $28.87 4/15/202525,460,000 shares $588.38 million -0.6%24.0%5.6 $23.11 3/31/202525,620,000 shares $618.72 million +5.8%24.1%5.6 $24.15 3/15/202524,210,000 shares $747.85 million +1.3%22.8%5.4 $30.89 2/28/202523,910,000 shares $690.28 million -4.8%22.5%5.6 $28.87 2/15/202525,110,000 shares $765.35 million +4.9%23.6%6.1 $30.48 Get the Latest News and Ratings for VKTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202523,930,000 shares $783.71 million +18.5%N/A5.9 $32.75 1/15/202520,200,000 shares $704.17 million +3.8%N/A4.3 $34.86 12/31/202419,470,000 shares $783.47 million +6.4%N/A4.5 $40.24 12/15/202418,300,000 shares $860.65 million +1.3%N/A4.3 $47.03 11/30/202418,070,000 shares $956.63 million +6.4%N/A4.3 $52.94 11/15/202416,990,000 shares $842.36 million +27.9%N/A4.1 $49.58 10/31/202413,280,000 shares $963.33 million -7.7%N/A3.4 $72.54 10/15/202414,390,000 shares $940.82 million -0.6%N/A4 $65.38 9/30/202414,480,000 shares $916.73 million -9.0%N/A4.1 $63.31 9/15/202415,910,000 shares $1.06 billion -7.2%N/A4.1 $66.73 8/31/202417,140,000 shares $1.10 billion -3.2%N/A4.5 $64.12 8/15/202417,700,000 shares $1.01 billion +5.0%N/A4.6 $57.00 7/31/202416,860,000 shares $961.02 million +11.7%N/A4.3 $57.00 7/15/202415,100,000 shares $896.64 million -10.3%N/A4.4 $59.38 6/30/202416,830,000 shares $892.16 million +32.8%N/A5 $53.01 6/15/202412,670,000 shares $659.09 million +2.9%N/A3.6 $52.02 5/31/202412,310,000 shares $766.42 million +1.2%N/A3.2 $62.26 5/15/202412,170,000 shares $949.38 million +0.5%N/A2 $78.01 4/30/202412,110,000 shares $963.71 million +8.6%N/A1.9 $79.58 4/15/202411,150,000 shares $746.49 million +17.1%N/A1.8 $66.95 3/31/20249,520,000 shares $780.64 million -14.5%N/A1.5 $82.00 3/15/202411,140,000 shares $696.92 million -9.3%N/A1.8 $62.56 2/29/202412,280,000 shares $946.17 million +2.2%N/A2.2 $77.05 2/15/202412,020,000 shares $382.84 million -7.0%N/A3 $31.85 1/31/202412,920,000 shares $311.89 million -5.8%N/A4.6 $24.14 1/15/202413,710,000 shares $293.94 million +1.9%N/A5.3 $21.44 12/31/202313,460,000 shares $250.49 million -7.8%N/A5.3 $18.61 12/15/202314,600,000 shares $275.94 million -5.3%N/A5.9 $18.90 11/30/202315,420,000 shares $188.43 million -9.1%N/A6.4 $12.22 11/15/202316,970,000 shares $187.18 million +3.4%N/A8.5 $11.033..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 10/31/202316,420,000 shares $161.08 million +11.0%N/A8.6 $9.81 10/15/202314,800,000 shares $162.06 million +6.6%N/A7.7 $10.95 9/30/202313,890,000 shares $153.76 million +1.8%N/A7.8 $11.07 9/15/202313,640,000 shares $201.46 million +5.7%N/A6.6 $14.77 8/31/202312,910,000 shares $178.29 million -5.0%N/A5.6 $13.81 8/15/202313,590,000 shares $201.27 million +14.8%N/A5.5 $14.81 7/31/202311,840,000 shares $171.68 million -2.7%N/A4.2 $14.50 7/15/202312,170,000 shares $189.61 million +0.7%N/A4 $15.58 6/30/202312,090,000 shares $195.98 million +9.2%N/A3.6 $16.21 6/15/202311,070,000 shares $248.63 million -6.9%N/A2.2 $22.46 5/31/202311,890,000 shares $261.10 million -1.2%N/A2.5 $21.96 5/15/202312,030,000 shares $264.54 million +3.8%N/A2.5 $21.99 4/30/202311,590,000 shares $246.98 million +1.3%N/A2.6 $21.31 4/15/202311,440,000 shares $214.50 million +1.6%N/A2.7 $18.75 3/31/202311,260,000 shares $187.48 million +112.1%N/A2.9 $16.65 3/15/20235,310,000 shares $56.71 million +9.5%7.8%1.8 $10.68 2/28/20234,850,000 shares $53.40 million +4.1%7.1%1.3 $11.01 2/15/20234,660,000 shares $51.91 million +17.7%6.9%1.3 $11.14 1/31/20233,960,000 shares $34.69 million -33.2%5.9%1.1 $8.76 1/15/20235,930,000 shares $53.07 million +4.2%8.9%1.7 $8.95 12/30/20225,690,000 shares $53.49 million +201.1%8.4%1.7 $9.40 12/15/20221,890,000 shares $7.28 million +6.8%2.8%0.6 $3.85 11/30/20221,770,000 shares $7.17 million -1.7%2.6%2.3 $4.05 11/15/20221,800,000 shares $8.05 million -5.3%2.7%2.4 $4.47 10/31/20221,900,000 shares $7.79 million +6.2%2.8%2.9 $4.10 10/15/20221,790,000 shares $5.85 million -4.8%2.7%2.6 $3.27 9/30/20221,880,000 shares $5.11 million -2.6%2.8%3 $2.72 9/15/20221,930,000 shares $6.41 million -4.5%2.8%2.2 $3.32 8/31/20222,020,000 shares $6.42 million -3.4%3.0%2.1 $3.18 8/15/20222,090,000 shares $8.13 million -3.7%3.1%1.9 $3.89 7/31/20222,170,000 shares $0.00 -11.4%3.2%1.9 $0.00 7/15/20222,450,000 shares $9.07 million -9.6%3.6%2.2 $3.70 6/30/20222,710,000 shares $7.83 million -41.1%3.9%2.4 $2.89 6/15/20224,600,000 shares $9.98 million -1.9%6.7%4.4 $2.17 5/31/20224,690,000 shares $10.41 million +4.5%6.8%4.9 $2.22 5/15/20224,490,000 shares $10.46 million +16.3%6.5%4.8 $2.33 4/30/20223,860,000 shares $9.19 million +4.3%5.6%3.9 $2.38 4/15/20223,700,000 shares $10.21 million +3.9%5.4%3.4 $2.76 3/31/20223,560,000 shares $10.68 million -20.2%5.1%3.2 $3.00 3/15/20224,460,000 shares $13.51 million +2.5%6.4%3.9 $3.03 2/28/20224,350,000 shares $14.57 million +4.8%6.2%4.1 $3.35 2/15/20224,150,000 shares $15.69 million -4.2%5.9%3.8 $3.78 1/31/20224,330,000 shares $16.06 million +19.0%6.2%4.5 $3.71 1/15/20223,640,000 shares $15.43 million -0.6%5.2%4 $4.24 12/31/20213,660,000 shares $16.84 million -12.0%5.3%5.1 $4.60 12/15/20214,160,000 shares $20.09 million -15.8%5.9%6.1 $4.83 11/30/20214,940,000 shares $26.23 million +3.4%7.0%8 $5.31 11/15/20214,780,000 shares $28.73 million -4.0%6.8%7.7 $6.01 10/29/20214,980,000 shares $28.98 million +4.8%7.1%8 $5.82 10/15/20214,750,000 shares $28.55 million -6.3%6.8%7.8 $6.013..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 9/30/20215,070,000 shares $31.84 million -13.5%7.2%8 $6.28 9/15/20215,860,000 shares $38.03 million -8.0%8.3%8.4 $6.49 8/31/20216,370,000 shares $42.11 million -13.7%9.1%7.9 $6.61 8/13/20217,380,000 shares $43.62 million -9.0%10.5%8.4 $5.91 7/30/20218,110,000 shares $49.88 million +2.8%11.6%9 $6.15 7/15/20217,890,000 shares $46.08 million -3.1%11.3%8.4 $5.84 6/30/20218,140,000 shares $48.76 million -17.8%11.6%8.3 $5.99 6/15/20219,900,000 shares $59.70 million -2.5%14.1%10.1 $6.03 5/28/202110,150,000 shares $53.19 million -5.8%14.5%11 $5.24 5/14/202110,770,000 shares $63.76 million +1.7%15.4%11.2 $5.92 4/30/202110,590,000 shares $66.29 million -4.6%15.2%9.5 $6.26 4/15/202111,100,000 shares $66.60 million +10.5%16.1%8.2 $6.00 3/31/202110,050,000 shares $60.90 million +18.0%15.5%7.1 $6.06 3/15/20218,520,000 shares $57.51 million +1.2%13.1%5.6 $6.75 2/26/20218,420,000 shares $57.93 million +1.7%13.0%5.5 $6.88 2/12/20218,280,000 shares $72.12 million -2.2%12.7%5.4 $8.71 1/29/20218,470,000 shares $63.69 million -3.5%13.1%5.8 $7.52 1/15/20218,780,000 shares $58.47 million -3.3%13.6%6.7 $6.66 12/31/20209,080,000 shares $53.03 million +3.1%14.0%7.4 $5.84 12/15/20208,810,000 shares $59.12 million -11.6%13.5%7.6 $6.71 11/30/20209,960,000 shares $66.53 million -7.0%15.3%8.4 $6.68 10/30/202010,140,000 shares $56.58 million -2.5%15.6%8.4 $5.58 10/15/202010,400,000 shares $60.89 million -7.1%16.0%8.5 $5.86 9/30/202011,200,000 shares $65.18 million +19.9%17.3%8.9 $5.82 9/15/20209,340,000 shares $58.38 million +7.1%14.4%7.1 $6.25 8/31/20208,720,000 shares $58.34 million -0.1%13.4%6.6 $6.69 8/14/20208,730,000 shares $64.25 million -17.6%12.3%6.5 $7.36 7/31/202010,590,000 shares $74.34 million +6.3%14.9%7.2 $7.02 7/15/20209,960,000 shares $68.23 million -16.4%14.1%6.4 $6.85 VKTX Short Interest - Frequently Asked Questions What is Viking Therapeutics' current short interest? Short interest is the volume of Viking Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 32,100 shares of VKTX short. 0.03% of Viking Therapeutics' shares are currently sold short. Learn More on Viking Therapeutics' current short interest. Which institutional investors are shorting Viking Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Viking Therapeutics: Jane Street Group LLC, Parallax Volatility Advisers L.P., Caption Management LLC, PEAK6 LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Capital Fund Management S.A., Simplex Trading LLC, National Bank of Canada FI, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Viking Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Viking Therapeutics' floating shares are currently sold short. Is Viking Therapeutics' short interest increasing or decreasing? Viking Therapeutics saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 32,100 shares, a decline of 99.9% from the previous total of 28,470,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Viking Therapeutics' short interest compare to its competitors? 0.03% of Viking Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Viking Therapeutics: Madrigal Pharmaceuticals, Inc. (22.78%), Eli Lilly and Company (0.91%), Moderna, Inc. (19.15%), Regencell Bioscience Holdings Limited (4.03%), Viatris Inc. (3.51%), Ascendis Pharma A/S (6.16%), QIAGEN N.V. (2.51%), Blueprint Medicines Corporation (5.95%), BridgeBio Pharma, Inc. (14.05%), Verona Pharma PLC American Depositary Share (0.60%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Viking Therapeutics stock? Short selling VKTX is an investing strategy that aims to generate trading profit from Viking Therapeutics as its price is falling. VKTX shares are trading down $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viking Therapeutics? A short squeeze for Viking Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VKTX, which in turn drives the price of the stock up even further. How often is Viking Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VKTX, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Madrigal Pharmaceuticals Short Squeeze Eli Lilly and Company Short Squeeze Moderna Short Squeeze Regencell Bioscience Short Squeeze Viatris Short Squeeze Ascendis Pharma A/S Short Squeeze QIAGEN Short Squeeze Blueprint Medicines Short Squeeze BridgeBio Pharma Short Squeeze Verona Pharma PLC American Depositary Share Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VKTX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
